Clinical Trials Logo

Castleman's Disease clinical trials

View clinical trials related to Castleman's Disease.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02853968 Completed - Hyperplasia Clinical Trials

Unlock the Cell: Castleman's Disease Flow Cytometry Study

Start date: February 2016
Phase:
Study type: Observational

Castleman disease, a rare lymphoproliferative disorder, is characterized by inflammatory cytokine production and multiple organ system dysfunction. In this study, we will investigate inflammatory markers, cells, and signaling pathways in prospectively collected blood samples and/or buccal swabs or saliva using biochemical and RT-PCR techniques, proteomics, genomics, immunohistochemistry, storage for future use, cell culture treated with external stimuli, flow cytometry, and other molecular tests

NCT ID: NCT01183598 Completed - Castleman's Disease Clinical Trials

A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment

Start date: August 2006
Phase: Phase 1
Study type: Interventional

This open-label, single center study will provide RoActemra/Actemra (tocilizumab) to a maximum of 4 patients with Multicentric Castelman's Disease who have demonstrated benefit from RoActemra/Actemra in study MRA004US (Chugai Pharma USA) without major toxicities or significant adverse events. Patients will receive their most effective maintenance dose until disease progression or significant toxicity occurs.